Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma

Abstract excerpt

Glypican-3 (GPC3) has emerged as a candidate therapeutic target in hepatocellular carcinoma (HCC), but the oncogenic role of GPC3 in HCC is poorly understood. Here, we report a human heavy-chain variable domain antibody, HN3, with high affinity (Kd = 0.6 nM) for cell-surface-associated GPC3 molecules. The human antibody recognized a conformational epitope that requires both the amino and carboxy terminal domains...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Galectins and Cancer Biology
• Share to Glycosylation and Glycoproteins Research
• Share to Monoclonal and Polyclonal Antibodies Research